Navigation Links
Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Date:11/15/2007

umococci, is a growing challenge when it comes to serious infections like CAP," said Dr. Donald Low, Head of the Division of Microbiology in the Department of Laboratory Medicine and Pathobiology at the University of Toronto in Toronto, Ontario. "Cethromycin, a new antibiotic, may be the solution to this important public health problem, as it has demonstrated a broad spectrum of antibacterial activity and an ability to overcome pneumococcal resistance in clinical trials."

Program Design

The Phase III CAP pivotal development program was comprised of two double-blind, randomized, well controlled, multi-center, multi-national, comparator trials designed to assess the safety and effectiveness of cethromycin in CAP patients compared to Biaxin. Trial CL-06 enrolled patients from clinics in Europe, South America and Israel and Trial CL-05 enrolled patients from the United States, Canada and South Africa. In both trials, cethromycin was evaluated using a 300 mg once-daily oral dosing regimen compared to 250 mg twice-daily dosing for Biaxin, both over a seven-day course of therapy. Biaxin is an FDA-approved standard of care antibiotic currently indicated for the treatment of CAP.

The primary endpoint for both trials was the clinical cure rate at the test-of-cure visit (Day 14-21 post-initiation of dosing). The eligibility of patients for each trial was based on clinical signs and symptoms as well as chest X-ray results as evaluated by an independent radiologist. Extensive electrocardiogram and liver function test monitoring were incorporated into the study design in order to examine safety in these areas and add to the safety database established in previous cethromycin clinical trials.

Results of Trial CL-05

In Trial CL-05, cethromycin met all efficacy endpoints and demonstrated a favorable safety profile as outlined below:

-- Per protocol clinical cure rate (PPc) -- cethromycin 94.0% (205/218)

compared to Biaxin 93.8% (195/208
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
4. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
5. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
6. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
(Date:1/14/2014)... 2014   NuAire , a manufacturer of ergonomically designed laboratory ... Koki of Japan to sell and ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... VIVUS, Inc. (NASDAQ: VVUS ) today announced that ... Congress on Obesity (ECO) in Istanbul, Turkey.  ECO is the ... of Obesity (EASO). ECO is regularly attended by more than ... be the most important annual scientific event on obesity in ...
... 2011 MicroVention-Terumo, Inc., a leader in developing, ... the final 18-month follow-up data in a landmark ... Packing Study (HELPS) published in The Lancet ... treating cerebral aneurysms reduced recurrence and retreatment rates ...
Cached Medicine Technology:Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 2Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 3Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 4Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 5Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumo's HydroCoil® Embolic System for Treatment of Cerebral Aneurysms 2Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumo's HydroCoil® Embolic System for Treatment of Cerebral Aneurysms 3Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumo's HydroCoil® Embolic System for Treatment of Cerebral Aneurysms 4
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
(Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... Nov. 19 Have you ever asked yourself, "What in the ... it,s safe to give your puppy a leftover turkey drumstick - ... , , To address these ... Association (AVMA) today launched a new podcast series, "Chew on This," ...
... “OneMedForum 2009” finance conference for emerging medtech companies ... Francisco at the Sir Francis Drake Hotel. The ... to be a vital resource for emerging medtech ... two-day OneMedForum event will include industry-focused panel sessions, ...
... PC Brands, a,California-based manufacturer of nutrition bars, today ... shelf stable all-natural bars. The,"on the go" bars ... does not require refrigeration. , ... in a 90-calorie Yogurt,Fruit and Nut with Cranberries, Almonds ...
... study by researchers at the Bradley Hasbro Children,s Research Center ... among teens and young adults particularly those who have ... that show anal sex rates among adults doubled between the ... the American Journal of Public Health , is among ...
... of thousands of Americans are injured or die on our nation,s ... scores in a new roadway safety scorecard released today by the ... and South Dakota received the lowest scores. The report, ... for Injury Prevention , examines roadway safety laws in all 50 ...
... developer of voice solutions for healthcare, has been ... to help researchers assess the impact of automated ... on commonly prescribed medications. Using interactive voice response ... healthcare providers to evaluate real time patient data. ...
Cached Medicine News:Health News:AVMA Launches 'Chew on This' Podcast Series on Food Safety 2Health News: OneMedPlace announces "OneMedForum 2009" finance conference for emerging medtech companies : Second annual event to be held January 13-14, 2009, in San Francisco 2Health News:PC Brands Introduces Great Tasting Shelf-Stable Nutrition Bar With Probiotics 2Health News:More at-risk teens and young adults engaging in anal intercourse 2Health News:Oregon, Washington State Doing the Most to Promote Roadway Safety, According to New Emergency Nurses Association National Scorecard 2Health News:Oregon, Washington State Doing the Most to Promote Roadway Safety, According to New Emergency Nurses Association National Scorecard 3Health News:Brigham and Women's Researchers Partner with Vocantas to use CallAssure in Clinical Research Study 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: